Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Travere Therapeutics (TVTX) PT Raised to $35 at Citi
February 24, 2025 4:58 AM ESTCiti analyst Carly Kenselaar raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $35.00 (from $31.00) while maintaining a Buy rating.
The analyst comments "We anticipate continued growth for FILSPARI in 2025, driven by 1) expected approval in FSGS in 4Q25 with an sNDA... More
